Roivant

relay

Biotech

Immunovant posts phase 3 autoimmune win but won't seek approval

Having made a next-gen asset its lead prospect last year, the biotech isn’t currently planning to file for batoclimab approval in myasthenia gravis.

Nick Paul Taylor Mar 19, 2025 9:15am

reducing people on team

Big Pharma layoff rounds jump 281% in 2024

Jan 3, 2025 3:29pm

Sketch of lungs

Roivant’s midstage asset fails to show benefit in lung disease

Dec 3, 2024 10:32am

Graphic of a pair of scissors cutting a 100 bill

Pfizer closes R&D unit that spawned $7.1B anti-TL1A med

Apr 17, 2024 7:00am

Graphic of a dart right on a bullseye sun breaking through the clouds in the background

Roivant's inflammatory med is back on track with ph. 2 NIU data

Apr 2, 2024 10:37am

light idea burst ruin destroy lightning shot

JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go

Jan 12, 2024 10:30am